

Index

a

- Acetaminophen (Paracetamol)
 - AERD 240
 - analgesic actions 394ff, 397, 407
 - analgesic nephropathy 222
 - asthma 257
 - hepatotoxicity 216
 - mode of action 82
 - osteoarthritis 407f
- Acetylsalicylic acid (ASA) *see aspirin*
- Acute coronary syndrome (see coronary vascular disease)
- Adenomatous polyposis coli (APC) 431ff
- Allodynia 143
- Alzheimer's disease 438ff
 - clinical trials 440ff
 - epidemiology 438
 - etiology 438
 - general aspects 438
 - mode of aspirin action 439f
 - NSAIDs 439f
 - pathophysiology 438f
- Anandamide 77, 85, 144
- Angioedema 244
- Anticoagulants
 - cerebrovascular disease 321ff
 - coronary vascular disease 295ff
 - NOAC 296
 - peripheral arterial disease 358
 - venous thrombosis 350
- Antiplatelet drugs 123
- Antipyretic analgesics 390ff
- Antitumorogenic effects of aspirin – *see malignancies*
- Apixaban (*see* NOAC)
- Aprotinin 187
- Arachidonic acid 77ff
 - metabolism via COX-1/2 122
- Arthritis (*see: Osteoarthritis, see: Rheumatoid arthritis*)
- Aspirin (*see also special items, see also “salicylate”*)
 - absorption 54ff
 - acetylation reactions 34, 66ff, 78ff, 89ff
 - alcohol 55
 - analgesic actions 25, 143ff, 390ff
 - analogues 34
 - angioedema 244f
 - antiinflammatory actions 15, 25, 95f, 138f, 273f
 - antiplatelet actions 115ff, 269f
 - antipyretic actions 15, 148ff, 394
 - antitumor effects 33, 153, 156ff, 419ff
 - antiulcer drugs 209
 - bioavailability 57
 - biotransformations 66ff
 - bleeding risk 26, 180, 184ff, 193, 292
 - bleeding-time 26f, 180ff
 - cerebrovascular diseases 307ff
 - chemical properties 43
 - coagulation factors 128, 182ff
 - coronary vascular disease 269ff
 - COX-independent actions 160ff
 - COX-inhibition 78ff
 - desensitization 239f
 - determination 47ff
 - diabetes 282f
 - dissolution 43, 55
 - distribution 60f
 - dosing 119ff, 171f, 180, 274f, 288f, 311f, 361ff, 380ff, 391ff
 - ductus arteriosus Botalli 193
 - elderly patients 193ff
 - endothelial protection 125ff
 - energy metabolism 18f, 101ff
 - esterases 66ff
 - excretion 71
 - fetal toxicity 191f
 - fertility 191f
 - fibrinolysis 128f, 286f
 - formulations 43, 57ff, 392ff
 - gene transcription 84f, 89ff
 - generics 43ff
 - GI-toxicity 198ff
 - habituation 177

- heart failure 224f
- heme oxygenase-1 126f
- hemostasis 113
- hepatotoxicity 216f
- history 5ff
- hypersensitivity (see “*aspirin exacerbated respiratory disease*, see “*urticarial/angioedema*”)
- hyperthermia 174, 394ff
- inflammation 136ff
- inhibition of prostaglandin synthesis 19, 76, 78ff
- inhibition of platelet function 118ff
- inhibition of platelet thromboxane formation 119ff
- inhibition of kinases 92ff
- interactions with NSAIDs 82ff, 123, 141ff, 297, 375f, 408
- interaction with salicylate 123
- metabolism – hepatic cytochromes 69
- miscarriage 192
- myocardial infarction – Craven studies 27
- modes of action 75ff
- nitric oxide production 91ff, 125ff
- nuclear factor κ B (NF κ B) 97, 161
- peripheral arterial disease 330ff
- pharmacokinetics 54ff.
- plasma levels 61f
- pregnancy 191ff
- prostaglandins 19f, 124f
- renal failure 223
- «resistance» (see *Aspirin “resistance”*)
- Reye’s syndrome 247ff
- sphingosine-1-phosphate 159f, 421f
- “Spanish flu” 172
- stomach (see also *GI tract*)
- surgical interventions 291ff
- synthesis 9ff
- teratogenicity 191f
- thrombin formation 116, 182ff
- toxicity 169ff
- transcription factors 96ff. 161
- urticaria 244f
- withdrawal 185f, 290, 292, 312
- aspirin exacerbated respiratory disease (AERD) 233ff
 - clinical trials 239f
 - COX1/2 238
 - epidemiology 233f
 - leukotrienes 234ff
 - lipoxins 236
 - mode of aspirin action 237f
 - pathophysiology 234
 - prostaglandins 237f
 - treatment 239ff
- “aspirin-induced asthma” (see *Aspirin exacerbated respiratory disease*, AERD)
- APHS 34f, 84, 126

- Aspirin “Resistance” 369ff
 - cardiovascular outcome 380ff
 - cerebrovascular disease 310ff
 - clinical trials 379ff
 - definition 370f
 - detection 371ff
 - general aspects 33f
 - phenotypes 373ff
 - thromboxane 372ff
- “Aspirin-triggered lipoxin (ATL)”
 - colorectal carcinomas 159, 421
 - gastric blood flow 205
 - general properties 22, 81f
 - eNOS stimulation 126f
 - preeclampsia 357f
- Audiovestibular system (see *ototoxicity*)

b

- Bleeding 26ff, 180ff
 - bleeding time 16, 180
 - bleeding risk in long-term prevention 184f
 - bleeding risk in surgical interventions 185, 292
 - GI bleeding 198ff
 - hemorrhagic stroke 307
 - pregnancy and labor 193
 - role of platelets 26
 - role of thromboxane 181
 - treatment 186f

c

- Cancer (see also *malignancies and colorectal cancer*)
- Cardiovascular disease (see: *coronary vascular diseases*)
- Cerebrovascular disease 307ff
 - anticoagulants 321f
 - cilostazol 321
 - clinical trials-primary prevention 312ff
 - clinical trials-secondary prevention 314ff
 - clopidogrel 318f
 - dipyridamole 319f
 - epidemiology 307
 - etiology 307
 - mode of aspirin action 308ff
 - NOAC 323
 - pathophysiology 307
 - platelets 308ff
 - stroke subtypes 313, 316ff
 - thromboxane 308f
- Cilostazol
 - cerebrovascular disease 321
 - mode of action 321
 - peripheral arterial disease 338f
- Clinical trials, types of 267
- Clopidogrel

- cerebrovascular disease 318f
- coronary vascular disease 288ff, 292ff
- mode of action 116
- peripheral arterial disease 337f
- “resistance” 370

Coagulation 128

Colorectal adenomas (*see: adenomatosis polyposis coli*)

Colorectal cancer 33, 153ff, 418ff

- aspirin-triggered lipoxin (ATL) 159, 421
- clinical trials-primary prevention 423ff
- clinical trials-secondary prevention 428ff
- COX-1 154f
- COX-2 154, 428f
- coxibs 408, 431f
- epidemiology 418
- etiology 418f
- Lynch syndrome 427f
- modes of aspirin action 156ff, 419ff
- NSAIDs 431f
- pathophysiology 154ff, 419
- prostaglandins 153
- sphingosine-1-phosphate 159f, 421f

Coronary vascular disease 269ff

- ACE inhibitors 296
- anticoagulants 295f
- aspirin, historical use of 27ff, 270
- clinical trials- Acute coronary syndrome (ACS) 285ff
- clinical trials-Primary prevention 275ff
- clinical trials-Secondary prevention 285ff
- clinical trials - Coronary artery bypass surgery (CABG) 291ff
- clopidogrel 292ff
- coxibs 408
- dual antiplatelet therapy 288, 292
- epidemiology 270
- etiology 269f
- mode of aspirin action 271ff
- NSAIDs 297, 408
- pathophysiology 269f
- percutaneous coronary interventions (PCI) 288
- platelets 271f
- statins 297, 382

COX (*see also isoforms*)

- atherosclerosis 124
- gastric mucosa 200ff
- general aspects 20f, 76ff
- gene expression
- historical aspects 13ff.
- inhibition by aspirin 78ff

COX-1

- antiplatelet actions of aspirin 115ff
- “aspirin-induced asthma” (AERD) 238f

- acetylation by aspirin 78ff
- colorectal cancer 154f
- general properties 76ff
- inhibition by with NSAIDs 82ff
- platelet function 79ff

COX-2

- acetylation by aspirin 21f, 80f
- colorectal cancer 154, 419ff
- general properties 76ff
- inflammation 137 ff
- lipoxins 81f
- platelet function 377
- stomach mucosa 200ff
- transcription factors 158

COX-3 77

Coxibs

- cardiovascular risk 408
 - colorectal cancer 431f
 - GI effects 209f
 - interactions with aspirin 408
- Craven, Lawrence L. 27f
- Cyclooxygenase(s) (*see COX*)

d

Dabigatran (*see NOAC*)

Deep vein thrombosis (*see: venous thrombosis*)

Desmopressin (DDAVP) 187

Diabetes 282ff

- antiplatelet action of aspirin 283f
- clinical trials with aspirin 224, 283
- thrombotic risk 282f

Dicarboxylic fatty acids 105ff, 248

Dipyridamole

- cerebrovascular disease 319ff
- mode of action 319
- peripheral arterial disease 338

Dipyrrone (Metamizole) 408f

Disease-modifying antirheumatic drugs (DMARDs) 405

Dresler, Heinrich 10

Ductus arteriosus Botalli 192f

Duisberg, Carl 9ff

e

Edoxaban (*see NOAC*)

Eichengrün, Arthur 9ff

Elwood, Peter C 29, 270

Endocannabinoids 144

Endothelium

- general aspects 123f
- inhibition of prostacyclin production by aspirin 81f, 124f
- anticoagulatory factors 123f

- atherosclerosis 124
- dysfunction 124f, 140f, 273, 331
- inflammation 140
- NO-synthase (eNOS) 91ff, 125f
- prostacyclin production 124f
- Energy metabolism 101ff
- modes of aspirin action 101
- modes of salicylate action 101ff
- oxidative phosphorylation 103f
- Reye's syndrome 108f (*see also* *Reye's syndrome*)
- uncoupling of oxidative phosphorylation 106ff

f

- Fatty acid metabolism 102ff
- Ferritin 126f
- Fertility 191f
- Fibrinolysis 128f
- Flu and feverish diseases 147f
 - aspirin modes of antipyretic action 148f
 - clinical trials 394
 - mediators of the febrile response 147f
 - salicylates 148f
 - spanish Flu 172

g

- Gastrointestinal (GI) tract 198ff
 - clinical trials 205ff
 - coxibs 209f
 - GI bleeding 205ff
 - helicobacter pylori 210
 - modes of aspirin action 201ff
 - NSAIDs 209
 - pathophysiology of GI injury 199ff
 - prostaglandins and cyclooxygenases 200ff
 - salicylate-induced stomach injury 202
- Gentisic acid 67, 71
- Gerhardt, Charles Frédéric 12

h

- Headache (*see also*: *tension-type headache, see: migraine*) 394ff
- Hearing disturbances (*see* *ototoxicity*)
- Heme oxygenase 126ff
- Hemorrhage (*see* *bleeding*)
- Hemorrhagic stroke (*see* *cerebrovascular diseases*)
- Hemostasis 113f
- HIV 404ff
 - clinical trials 407
 - modes of aspirin action 405
 - pathophysiology 404
- Hoffmann, Felix 9ff
- Hypertension 224, 281, 296f
- Hypertension in pregnancy (*see*: *preeclampsia*)

i

- Ibuprofen 83, 123, 297, 397, 408ff
- Inflammatory diseases 401ff
 - general aspects 136f
 - HIV 404ff
 - inflammatory mediators 137f
 - lipoxins 140
 - mode of aspirin action 138ff
 - osteoarthritis 403ff
 - rheumatoid arthritis 402ff
 - systemic inflammatory response syndrome (SIRS) 403ff
- Ischemia (*see* *particular organs*)
- Isoprostanes 378f

k

- Kawasaki's disease 256, 414ff
 - clinical trials 415
 - etiology 414
 - mode of aspirin action 414f
 - pathophysiology 414
- Kidney
 - analgesic nephropathy 219f
 - clinical trials 221ff
 - general aspects 219
 - mode of aspirin action 220f
- Kinases
 - inhibition by salicylates 92ff
 - role in inflammation 95
- Kolbe, Hermann 6
- Kune, Gabriel 33, 423

l

- Leukotrienes
 - asthma 234ff
 - inflammation 137f
 - ototoxicity 230
- Lipoxins (*see also* *aspirin-triggered lipoxin*)
 - aspirin-triggered lipoxin (ATL) 22, 81f
 - inflammation 137ff
 - stimulation of NO production 126
 - preeclampsia 357f
- Liver
 - clinical trials 216f
 - mode of aspirin action 216f
 - general aspects 216
- Lyell syndrome 245
- Lynch syndrome 427f

m

- Malignancies (*see*: *cancer*)
- Metamizol (*see*: *dipyrone*)

Methylsalicylate 43
 Migraine 395f
 Myocardial infarction (*see coronary vascular disease*)

n

New oral anticoagulants (*see NOAC*)
 NOAC
 – coronary vascular disease 296
 – cerebrovascular disease 323
 – peripheral arterial disease 338
 – venous thrombosis 350f
 Nonsteroidal antiinflammatory drugs (NSAIDs)
 (*see also particular compounds*)
 – AERD 237
 – antiplatelet effects 375ff
 – Alzheimer's disease 440ff
 – colorectal carcinoma 431f
 – coronary vascular disease 297
 – COX-inhibition 82f
 – ductus arteriosus 192f
 – fertility 191
 – GI-effects 202ff, 209
 – interaction with antiplatelet effects
 of aspirin 83, 297, 375f, 408
 – mode of action 82f, 404
 – renal effects 221ff
 Nuclear factor κ B (NF κ B) 97, 161

o

Organ toxicity (*see individual organs*)
 Osteoarthritis
 – clinical studies 405f
 – mode of aspirin action 403
 – pathophysiology 403
 Ototoxicity 228ff
 – clinical trials 230
 – leukotrienes 230
 – mode of aspirin action 228ff
 – pathophysiology of hearing loss 228
 – prestin 228f
 – prostaglandins 230
 – tinnitus 229
 Oxidative phosphorylation (*see: energy metabolism*)

p

Pain 136ff, 142ff, 390ff
 – acetaminophen 394f
 – endocannabinoids 144
 – mediators of pain 142f
 – headache 395f
 – migraine 395f
 – modes of aspirin action 143ff
 – prostaglandins 142f
 – serotonin 144f

Paracetamol (*see: acetaminophen*)
 Peripheral arterial disease (PAD) 330ff
 – anticoagulants 338
 – cilostazol 338f
 – clopidogrel 337f
 – coagulation 331f
 – dipyridamole 338
 – endothelial dysfunction 331
 – epidemiology 330
 – etiology 330
 – clinical trials-Peripheral transluminal
 angioplasty 336f
 – clinical trials-Primary prevention 332ff
 – clinical trials-Secondary prevention 334ff
 – mode of aspirin action 331ff
 – pathophysiology 330
 – platelet function 330f, 381
 – thromboxane 331f

Phenacetin 320

Plants

– salicylate and plant resistance 89
 – vegetables as sources of salicylates 6, 42

Platelets

– aspirin-dosing 121, 274f, 311f, 361ff, 380ff
 – bleeding time 26f
 – colorectal carcinomas 153, 421f
 – COX-1 78f, 377
 – general aspects 268, 271
 – inflammation 34, 115ff, 273ff
 – measurement of platelet function 128ff,
 308ff, 371ff
 – mode of aspirin action 78ff, 115f
 – response variability (*see Aspirin "resistance"*)
 – thromboxane formation 116ff, 271ff
 – tumorigenesis 153, 421f
 – turnover rate 283f, 379
 – venous thrombosis 343f

Preeclampsia 354 ff

– aspirin dosing 361f
 – diagnostics 364
 – epidemiology 354
 – etiology 354
 – clinical trials 358ff
 – lipoxins 357
 – mode of aspirin action 355f
 – pathophysiology 354f
 – prostacyclin 355
 – thromboxane 356f

Pregnancy

– aspirin use 191ff
 – ductus arteriosus Botalli 192
 Pregnancy-induced hypertension (*see: preeclampsia*)
 Prestin 228f

Prostacyclin (*see also prostaglandins*)

- atherosclerosis 124
- endothelial cells 123ff
- preeclampsia 355f

Prostaglandins

- biosynthesis 78
- general aspects 20f
- malignancies 153
- pain mediators 137f
- synthase(s) (*see COX*)

Pulmonary embolism (*see: venous thrombosis*)

r

Reye's syndrome 247ff

- acetaminophen 257ff
- aspirin 247ff
- clinical trials 252ff
- etiology 249
- history 247f
- laboratory findings 248f
- metabolic actions of salicylate 108f
- morphological findings 249
- pathogenesis 249f
- salicylates and xenobiotics 174
- symptoms

Rheumatoid arthritis 402ff

- clinical studies 405
- mode of aspirin action 402f
- pathophysiology 402

Rivaroxaban (*see NOAC*)

s

Salicin

- history 6
- chemistry 41f

Salicylate

- antiinflammatory actions 95, 138f, 401ff
- antipyretic actions 148f
- antirheumatic actions 7
- biotransformations 70f
- bleeding 180f
- chemical properties 41ff
- determination 47ff
- energy metabolism 18f, 106ff
- excretion 71
- fatty acid metabolism 102ff
- gastric mucosal injury 10, 56, 202f
- history 6ff
- inhibition of kinases 92 ff
- inhibition of prostaglandin synthesis 138f
- natural sources of 6f, 432
- pharmacokinetics 70ff
- plant resistance 89f

- plasma levels 61ff, 109

- protonophoric properties 106f

- synthesis of 6f

- toxicity 170ff

- transcription factors 96ff, 161

- uncoupling of oxidative phosphorylation (*see: energy metabolism*)

Salicylic acid (*see salicylate*)

Salicyluric acid 71

Serotonin (5-Hydroxytryptamin) 144f, 308

Sphingosine-1-phosphate 159f, 421f

Statins 297

Stevens-Johnson syndrome 245

Stomach (*see also: gastrointestinal system*)

- aspirin absorption 54f

- bleeding

- gastric mucosal injury by aspirin 199f

- helicobacter pylori 210f

- “Ion trapping” 56

Stone, Edward 5

Stroke (*see Cerebrovascular diseases*)

Surgical interventions 184ff

- aspirin withdrawal 184f, 290, 292

- bleeding 290

- coronary artery bypass surgery 291f

Systemic inflammatory response syndrome (SIRS) 403ff

- clinical trials 406

- mode of aspirin action 404

- pathophysiology 403

t

Tension-type headache 395f

Thrombin 116, 182ff, 272, 285

Thrombosis

- arterial thrombosis 269f

- general aspects 114f

- venous thrombosis 343f

Thromboxane (A₂)

- aspirin “resistance” 372ff

- biosynthesis 78

- PAD 331

- paracrine platelet functions 117f

- preeclampsia 356f

- stroke 308ff

- urinary excretion 372f

Tinnitus (*see: ototoxicity*)

Toxicity (*see also individual organs*)

- acute toxicity 170f

- children 174

- clinical symptoms 173

- general aspects 170f

- laboratory findings 173

- pathophysiology 172

- Reye's syndrome (*see also* *Reye's syndrome*) 174
 - treatment 175
- Trinder assay 47, 251

u

Urticaria 244f

v

Vane, Sir John R. 19f

Venous Thrombosis 343ff

- clinical trials-primary prevention 344ff
- clinical trials-secondary prevention 348ff
- etiology 343
- long-distance flights 348
- mode of aspirin action 343f

- pathophysiology 343
- platelets 343f

v

Von Heyden, Friedrich 6f

w

Warfarin (*see anticoagulants*)

Widal's Triad (*see: Aspirin exacerbated respiratory disease*)

Willow bark 5, 401

Witthauer, Kurt 15

Wu, Kenneth K. 22

